Neurologic diseases and neurogenetics
PRINCIPAL INVESTIGATORS
- Lucía Aja Rodríguez
- Helena Bejr-Kasem Marco
- Matilde Calopa Garriga
- Pedro Cardona Portela
- Maria Mercedes Falip Centellas
- Jordi Gascon Bayarri
- Mariano Huerta Villanueva
- Serge Jauma Classen
- Sergio Martínez Yélamos
- Julia Miró Lladó
- Monica Povedano Panades
- Joan Prat Rojo
- Cristina Sanchez Castañeda
CLINICAL RESEARCHERS
- Pablo Arroyo Pereiro
- Laura Bau Vila
- Jaume Campdelacreu Fumado
- Pere Domènech Santasusana
- Raúl Domínguez Rubio
- Dolors Dot Bach
- Isabel Fernández Conejero
- Laura González Mera
- Blanca Lara Rodríguez
- Maria Isabel Leon Moreno
- Elisabet Matas Martín
- Albert Muñoz Vendrell
- Velina Nedkova Hristova
- Andres Julian Paipa Merchan
- Lucia Maria Romero Pinel
- Elisabet Romero Gangonells
- Misericordia Veciana Veciana De Las Heras
PREDOCTORAL RESEARCHERS
- Roser Gomez Llopico
- Yaiza Lopez Sampere
- Pol Mengod Soler
- Silvia Muñoz Quiñones
- Estefania Riera Nuñez
- Sergio Roca Pereira
SCIENTIFIC SUPPORT
- Sheila Álvarez Fornieles
- Eloy Conde Gonzalvo
- Isabel Esteban Barrigon
- Antonia Vinyals Rioseco
- Gisela Zamorano Garcia
MANAGEMENT SUPPORT
- Guillem Borges Ballester
- José Luis Moreno Morejón
- Susana Pobla Müller
- Cristina Terrafeta Pastor
Neuroscience
Neuroscience
Scientific production
76
PAPERS
Average IF: 4,92
18
LED PAPERS
Average IF: 3,66
24 PUBLICATIONS IN FIRST DECILE
44 PUBLICATIONS IN FIRST QUARTILE
49 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Muñoz Vendrell,A;Campoy Díaz,S;Valín Villanueva,P;Casas Limón,J;Fernández Lázaro,I;González García,N;Santos Lasaosa,S et al, Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response., J. Headache Pain, 2025;27(1):2-2, doi:10.1186/s10194-025-02239-1
- Gascon Bayarri,J;Rico,I;Sanchez Castaneda,C;Ledesma,MD;Carnaval,T;Bejr Kasem,H;Campdelacreu,J et al, Efficacy and safety of efavirenz in Niemann-Pick disease type C, Neurotherapeutics, 2025;22(5):doi:10.1016/j.neurot.2025.e00706
- Matas,E;Bau,L;Romero Pinel,L;Leon,I;Arroyo Pereiro,P;Muñoz Vendrell,A;Martinez Yelamos,A et al, Benign multiple sclerosis and long-term outcomes after 30 years, J Neurol, 2025;272(11):747-747, doi:10.1007/s00415-025-13402-8
- Mcfarlane,R;Ross,R;Domhnaill,EM;Chio,A;Corcia,P;Ingre,C;Mcdermott,CJ et al, Dynamic modelling of the ALSFRS-R: leveraging population-based scores using neural networks, EBioMedicine, 2025;122106029-106029, doi:10.1016/j.ebiom.2025.106029
- Ezcurra Diaz,G;Cardona,P;Rodriguez Villatoro,N;Cubero,A;Flores Pina,B;Figueras Aguirre,GL;Fernandez Perez,I et al, Emergent Carotid Artery Stenting in Patients With Acute Ischemic Stroke With Tandem Lesions: One-Year Follow-Up Results From the SECURIS Study, Neurology, 2025;105(7):doi:10.1212/WNL.0000000000214067,
Research highlights
PROJECTS
2 Granted competitive projects
6 Ongoing competitive projects
14 Started clinical trials
58 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical guideline
INNOVATION
1 Patent
1 License
NETWORKS
TRICALS
RETICS- REEM
CSUR
XUEC
ENCALS
ERN
CIBERNED
Selected projects
- CPP2021-008378. Clinical trial to evaluate the administration of ApTOLL in ambulances and the neuroprotective effect in stroke patients. RACETOLL. Ministerio de Ciencia e Innovación. Budget: 487.992,8€. 2022-2025. PI: PEDRO CARDONA PORTELA.
- PI25/00583. Interacción entre el sistema sanguíneo periférico y el espectro ALS-FTD: implicaciones para la progresión de la enfermedad, el fenotipo clínico y la fisiopatología de las neuronas motoras (PERSYALS). Instituto de Salud Carlos III (ISCIII). Budget: 156250€. 2026-2028. PI: MONICA POVEDANO PANADES.
- EFC17504. ESTUDIO DE FASE 3, DOBLE CIEGO, ALEATORIZADO, COMPARANDO LA EFICACIA Y SEGURIDAD DE FREXALIMAB (SAR441344) CON PLACEBO EN PARTICIPANTES ADULTOS CON ESCLEROSIS MÚLTIPLE SECUNDARIA PROGRESIVA SIN RECAÍDAS. Sanofi Aventis Recherche & Développement. Budget: 341.480€. 2024- . PI: SERGIO MARTÍNEZ YÉLAMOS.
- BHV7000-303. A PHASE 2/3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF BHV-7000 IN SUBJECTS WITH REFRACTORY FOCAL ONSET EPILEPSY. Biohaven Pharmaceuticals, Inc. Budget: 46.592€. 2024- . PI: MARIA MERCEDES FALIP CENTELLAS.
- EDG-5506-201. Estudio de fase II, aleatorizado, con doble enmascaramiento y comparativo con placebo para evaluar el efecto de EDG-5506 en la seguridad, los biomarcadores, la farmacocinética y las medidas funcionales de adultos y adolescentes con Distrofia Muscular de Becker. EDGEWISE THERAPEUTICS INC.. Budget: 37.856,24€. 2024- . PI: VELINA NEDKOVA HRISTOVA.